Posts tagged Nabi-HB
Maxim upgrades ADMA Biologics to buy

Maxim Group upgraded ADMA Biologics (NASDAQ:ADMA) to ‘buy” from “hold” and established a price target of $13 after the company agreed to acquire Biotest Pharmaceuticals’ immunoglobulin manufacturing facility in Florida. The stock was quoted at $5.54 in afternoon trading on Jan. 24.

Read More